Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
Status:
Completed
Trial end date:
2021-07-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide critical information on the safety, reactogenicity
and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type
155-vectored RSV (ChAd155-RSV) vaccine in infants likely to be unexposed to RSV, and will
assess a single lower dose and a higher two dose regimen, before moving to future studies.
This study will also assess if there is a risk of 'vaccine-induced enhanced RSV disease'
after vaccination of these infants with the ChAd155-RSV vaccine.